Introduction
Non-Hodgkin lymphoma (NHL) is cancer of the lymphatic system, which represent a group of malignant lymphomas whose common feature is absence of the ReedSternberg cells characteristic of Hodgkin disease. Because lymphatic tissue is found in many parts of the body, NHL can start almost anywhere.
1, 2 NHL is the 6 th among the commonest ten cancers in Iraq and constitutes 5.52% of all cancers in both genders . 3 NHL is the 3 rd among the commonest ten cancers in Kurdistan Region in Iraq and constitutes 8.72% of all cancer in females and 12.46% in males. 4 NHL is the seventh most common cancer in the US, and age-adjusted incidence rose by more than 82.5% from 1975 to 2008. 5 There were an estimated 356000 new cases of NHL and 192000 deaths from NHL worldwide in 2008. 6 There is a large variation in the geographical distribution of NHL types, with a higher proportion of follicular and diffuse lymphoma in North America and Europe, and a higher proportion of T-cell lymphoma in Asia. 7 Part of the difference might be due to a greater variability in the incidence of B-cell NHL compared with T-cell NHL. 8 There are many types of NHL. Sometimes they are grouped as aggressive lymphomas, which are also called intermediate-grade and high-grade lymphomas. These cancers tend to grow and Background and objective: Non-Hodgkin lymphoma is a cancer of the lymphatic system. Types of non-Hodgkin lymphoma vary significantly in their severity from indolent to very aggressive. The aim of this study was to investigate the incidence, immunohistochemical expression, clinical and histopathological prognostic factors of patients with non-Hodgkin lymphoma. Methods: A total of 59 patients with non-Hodgkin lymphoma cases were reviewed and investigated at Razgary Teaching Hospital in Erbil city during the period from January, 2011 to January, 2013. Data of patients were tabulated and distributed according to their age, sex, site, immunohistochemical expression and WHO classification. Results: Age of non-Hodgkin lymphoma patients ranged from 2 to 88 years with a mean of 45 year. Around 49% of the patients were of age group over 50 years and 54.2% of patients were male. Immunohistochemical investigation indicated that 71.2% of non-Hodgkin lymphomas were of B cell type, the highest percentage (33.3%) of them was of diffuse large cell type. While the T cell type was found in 20.3%, the highest percentage (33.3%) of them was of Anaplastic lymphoma. CD20 and CD3 showed more consistent and strong expression for B and T cells non-Hodgkin lymphoma, respectively. Results showed high BCL2 expression. Nodal non-Hodgkin lymphoma account for 50.8% of the total cases. 10 The aim of this study is to detect the incidence, immunohistochemical expression as well as clinical and histopathological prognostic factors of patients with NHL in Erbil city, Kurdistan.
Conclusion
goodness of fit. A P value of less than 0.01 was considered highly significant and that less than 0.05 was considered statistically significant.
Methods
A retrospective review of 59 cases with NHL were retrieved from Razqari Teaching Hospital at Histopathology Laboratory during the period from January, 2011 to January, 2013 in Erbil city, Kurdistan, Iraq. Clinical information about gender, age, site of lesion were considered. Haematoxylin, eosin staining and immunohistochemical investigation with panel of antibodies consisted of CD20, CD3, CD79α and BCL2 were obtained from the laboratory. Primary monoclonal antibody used is of purified liquid form. For the avidin-biotin complex (ABC) detection system (secondary detection system), alkaline phosphatase method was used. The immunorecipient visualized as brown color in the cytoplasmic side of the cell membrane for all markers. Immunohistochemical staining for each antibody was recorded either positive/ negative, normal/abnormal, individual scattered cells/clusters, small/large cells, and percent of biopsy involved (<1%, 1-5%, or >5%). 11 The presence of clusters of cells was classified as abnormal (positive) when there were large number of clusters (>5%), which express the antibodies. Data was analyzed using Chi square test of
Results
Of 59 patients with NHL, 32 patients (54.2%) were male, and 27 patients (45.8%) were female (Table 1) . There was no significant difference between male and female patients. The age of NHL patients ranged from 2 to 88 years with a mean of 45 years. There was a highly significant difference among the age groups. The highest percentage of patients (49.2%) were of age group of >50 years old. The lowest percentage of patients (20.3%) were of age group of ≤ 25 years old ( Table  2 ). There were highly significant differences in the sites of NHL. The commonest primary site of NHL was lymph nodes (cervical, axillary and inguinal) which were found in 30 out 59 patients (50.8%) followed by 12 patients (20.3%) in bone marrow. Eight patients (13.6%) were found in gastrointestinal tissues. Low percentages were found in retroperitoneal (3.4%), brain (3.4%) and nose (3.4%) ( Table 3) . Majority of the patients (42 cases, 71.2%) with NHL were of B cell type (Figure 2) . T cell type constituted 20.3% (12 patients) ( Figure 3 and Table 4 ). The percentages of different types of B cells lymphoma were significantly different (P<0.01) ( Table 5) . Diffuse large B cell type was counted in 4 patients (33.3%). Eight patients (19.1%) found to have small B cell lymphoma. Follicular lymphoma was diagnosed in 6 patients (14.3%) while small noncleaved cell lymphoma (Burkitt lymphoma) was diagnosed in 3 patients (7.1%). Table 6 presents the percentages of different types of T cells, which show a highly significant difference (P < 0.01). Anaplastic lymphoma cell type was counted in 4 patients (33.3%). Three patients (25%) found to have peripheral T cell type. Three patients (25%) found to have lymphoblastic lymphoma. The expression of CD20 was positive in 46 patients (78%) and negative in 13 cases (22%) the difference was highly significant (P < 0.01). The expression of CD79α was positive in 40 patients (67.8%) and negative in 19 cases (32.2%). The difference was highly significant (P < 0.01). The expression of CD3 was positive in 18 patients (30.5%) and 41 patients (69.5%) with negative CD3 expression. The difference was highly significant (P < 0.01). The expression of BCL2 was negative in 39 patients (66.1%) whereas positive BCL2 was found in 20 patients (33.9%). The difference was highly significant (P < 0.01) as shown in Figure 1 . 
Discussion
NHL is malignant tumor with lymphatic system origin. Many different types of NHL have been described. 13 The current study revealed that males were marginally predominant (54.2%) to females (45.8%). This result had a similar trend with another study conducted in Sulaimania and Dohuk, Iraq, 14 which reported 66.8% were male and 33.1% were female. Results revealed that the majority (49.2%) of patients were of age group over 50 years which agreed by another study. 14 The result of this study showed that 71.2% of all NHL was of B cell type while T cell type rate was 20.3%. This result is similar to another study which showed 72% B cell expression, 22.5% T cell expression and 5.5% did not express any marker, 15 while another study revealed that 91% of patients with NHL was of B cell type, while T cell type rate was 9%.
14 Among all patients with B cell type NHL, the diffuse large cell was of the highest percentage (33.3%). Results of another study reveled that diffused large cell type was the commonest B cell type NHL (52.2%) followed by Burkitt's lymphoma (14.6%).
14 In another study, B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell type. 15 The current study showed that the most common type of T cell NHL was Anaplastic lymphoma (33.3%), which is close to result (26.3%) of another study.
14 On the other hand, another study showed that the commonest T-cell lymphoma was T lymphoblastic lymphoma (67%). 15 This variation has been attributed to geographic and racial cause. 16 This study showed that most NHLs were of intermediate-high grade. The results also showed extra nodal NHL accounted for 49.2% of the total cases. This is comparable to the rates observed in another study (48.3%).
14 Immunohistohemistry is an important technique in many challenging lymphoma cases . 17 In this study a panel of antibodies consisted of CD20, CD3, CD79α and BCL2 were studied. Variable expression was noted on the two B-cell markers CD20 and CD79α, with CD20 showing more consistent and strong expression; this result also agreed by others. 11, 18 CD79α had also been detected in 10 to 50% of precursor T-cell acute lymphoblastic lymphoma making this marker less reliable as an indicator of B-cell lineage. 19 Furthermore, CD3 was the most commonly used pan-T-cell antigen but natural killer cells can also express CD3. 18 Marginal zone lymphoma, follicular lymphoma and some diffuse large cell lymphoma are BCL-2 positive and also BCL-2 expression was variable geographically. 18 These factors lead to the high BCL-2 expression found in this study. In addition, it should always be remembered that no antigen is totally specific; therefore immunostaining must be interpreted in the context of a panel to avoid errors. 18 
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Most NHLs were of B cell type and highest percentage is of diffuse large cell type. CD20 and CD3 were more reliable as an indicator of B & T cell lineage, respectively. Most NHLs were of intermediate-high grade. Nodal site represent highest rate for primary NHL. Further study with long and short follow up of patients is a vital issue. It is also recommended to study the relations between immunohistochemical expressions and molecular genetics markers in different types of NHLs. Identifying such molecular markers can speed up diagnosis at early stage of life.
Conclusion

